Back to Search Start Over

Pharmacological evaluation of novel 5-HT 3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery

Authors :
Deepali Gupta
Mahesh Radhakrishnan
Devadoss Thangaraj
Yeshwant Kurhe
Source :
Journal of Pharmacy and Bioallied Sciences, Vol 7, Iss 2, Pp 103-108 (2015)
Publication Year :
2015
Publisher :
Wolters Kluwer Medknow Publications, 2015.

Abstract

Objective: In the last few decades, serotonin type-3 (5-HT 3 ) receptor antagonists have been identified as potential targets for anxiety disorders. In preclinical studies, 5-HT 3 antagonists have shown promising antianxiety effects. In this study, a novel 5-HT 3 receptor antagonist, QCM-13(N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) was evaluated for anxiolytic-like activity in rodent behavioral test battery. Materials and Methods: Mice were given QCM-13 (2 and 4 mg/kg, intraperitoneally [i.p.]) or diazepam (2 mg/kg, i.p.) or vehicle and after 30 min, mice were subjected to four validated behavioral test batteries viz. elevated plus maze, hole board, light-dark and open field tests. Interaction study of QCM-13 with m-chlorophenyl piperazine (mCPP) (mCPP, a 5-HT 2A/2C receptor agonist, 1 mg/kg, i.p.) and buspirone (BUS, a partial 5-HT 1A agonist, 10 mg/kg, i.p.) were performed to assess the pharmacological mechanism of the drug. Results: QCM-13 expressed potential anxiolytic effect with significant (P < 0.05) increase in behavioral parameters measured in aforementioned preliminary models. Besides, QCM-13 was unable to reverse the anxiogenic effect of mCPP, but potentiated anxiolytic affect of BUS. Conclusion: The results suggest that QCM-13 can be a potential therapeutic candidate for the management of anxiety-like disorders and combination doses of novel 5-HT 3 receptor antagonist with standard anxiolytics may improve therapeutic efficacy.

Details

Language :
English
ISSN :
09757406 and 09764879
Volume :
7
Issue :
2
Database :
Directory of Open Access Journals
Journal :
Journal of Pharmacy and Bioallied Sciences
Publication Type :
Academic Journal
Accession number :
edsdoj.5d21761bb6c447a914be513c5bdf31d
Document Type :
article
Full Text :
https://doi.org/10.4103/0975-7406.154429